Hennion & Walsh Asset Management, Inc. Athenex, Inc. Transaction History

Hennion & Walsh Asset Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 19, 2022	SELL	$0.41 - $0.91 $84,231 - $186,952	-205,442 Closed	0 $0
Q1 2022 Apr 26, 2022	SELL	$0.79 - $1.59 $8,167 - $16,437	-10,338 Reduced 4.79%	205,442 $170,000
Q4 2021 Feb 14, 2022	SELL	$1.36 - $2.94 $143,904 - $311,087	-105,812 Reduced 32.9%	215,780 $293,000
Q3 2021 Nov 12, 2021	SELL	$2.97 - $4.84 $45,539 - $74,211	-15,333 Reduced 4.55%	321,592 $968,000
Q2 2021 Aug 13, 2021	BUY	$3.71 - $5.13 $34,254 - $47,365	9,233 Added 2.82%	336,925 $1.56 Million
Q1 2021 May 17, 2021	BUY	$4.08 - $14.75 $1.34 Million - $4.83 Million	327,692 New	327,692 $1.41 Million

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.